Overview
Clinical Meaning
Parkinson disease results from progressive loss of dopaminergic neurons in the substantia nigra pars compacta, creating a dopamine acetylcholine imbalance in the striatum.
WHNP
WHNP
Parkinson disease results from progressive loss of dopaminergic neurons in the substantia nigra pars compacta, creating a dopamine-acetylcholine imbalance in the striatum. Pharmacotherapy targets multiple points in the dopaminergic pathway: levodopa (dopamine precursor) crosses the blood-brain barrier and is converted to dopamine by aromatic L-amino acid decarboxylase (AADC); carbidopa inhibits peripheral AADC to prevent peripheral conversion and reduce nausea/hypotension; COMT inhibitors (entacapone, opicapone) block peripheral degradation of levodopa extending its half-life; MAO-B inhibitors (selegiline, rasagiline, safinamide) prevent synaptic dopamine breakdown; dopamine agonists (pramipexole, ropinirole, rotigotine) directly stimulate D2/D3 receptors; and anticholinergics (benztropine, trihexyphenidyl) restore balance by reducing cholinergic excess.
Unlock full lesson + practice questions
4 more sections with scenarios, priorities, and review drills.
Next study step
Finish the lesson first, then choose a focused activity to apply what you just reviewed.
Continue studying
Sign in to save progress on this lesson.
Unlock the interactive lesson quiz with a plan that includes this WHNP pathway. You can still explore topic-filtered questions from the bank hubs below.